ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Legacy CEO Cheryl Healton says foundation could serve as funder for research on “potentially reduced-exposure products.”

October 29, 2004

NCI CTEP-Approved Trials For the Month of August

August 29, 2014

Reinventing NCI: Clinical Trials System Changes Not Easy Or Quick, Klausner Says; NCAB Members, Others, Sound Off On Group’s Report

October 10, 1997

Funding Opportunities.

May 10, 2002

Congress Approves FY 2010 Budget. Loehrer Named Interim Director At Indiana

April 10, 2009

NSABP Objects to “Closed Process” For Review Of P-4 Breast Cancer Chemoprevention Trial.

April 20, 2007